Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib.

Girija Dasmahapatra, Hiral Patel, Jawad T.J. Al-Khafaji, MD, Richard I Fisher, MD, Jonathan W. Friedberg, MD, Steven Grant, MD

Blood (2012) 120 (21): 2765.

https://doi.org/10.1182/blood.V120.21.2765.2765

Published: 2012

Journal Articles

Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo

Girija Dasmahapatra, Dmitry Lembersky, Jonathan W. Friedberg, MD, Richard I Fisher, MD, Paul Dent, Steven Grant, MD

Blood (2010) 116 (21): 3938.

https://doi.org/10.1182/blood.V116.21.3938.3938

Published: 2010

Journal Articles

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, Richard I. Fisher, Jonathan Friedberg, Paul Dent, Steven Grant

Blood (2010) 115 (22): 4478–4487.

https://doi.org/10.1182/blood-2009-12-257261

Published: 2010

Includes: Supplemental data

Journal Articles

The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage..

Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, Jonathan W. Friedberg, MD, Richard I Fisher, MD, Paul Dent, Steven Grant, MD

Blood (2009) 114 (22): 1688.

https://doi.org/10.1182/blood.V114.22.1688.1688

Published: 2009

Journal Articles

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism

Girija Dasmahapatra, Mohamed Rahmani, Paul Dent, Steven Grant

Blood (2006) 107 (1): 232–240.

https://doi.org/10.1182/blood-2005-06-2302

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib.

Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage..

The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism

Email alerts

ASH Publications

American Society of Hematology